Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Among patients with type 2 diabetes and peripheral artery disease or foot ulcers, the use of semaglutide is linked to a ...

If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Popular anti-obesity medications continue to be effective for weight loss even when availability and access is interrupted, ...

The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in.  | Novo ...

A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by rising obesity and type 2 diabetes incidences, the ...

Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently ...

Dear J.H.: Metformin, a treatment for diabetes that works mostly by preventing the liver from making sugar, isn't new and has ...